BioSpace News Archive

TG Therapeutics, Inc. (NASDAQ: TGTX), today announced two triple therapy combination data

Economic activity in the hospital subsector grew in November for the sixth consecutive month, say the nation’s hospital supply executives in the latest Hospital ISM® Report On Business®.

- STRO-001 was generally well-tolerated in patients with late-line NHL with no ocular or neuropathy toxicity signals; MTD has not been reached - - 1 CR & 2 PRs observed in heavily pretreated patients with DLBCL; 1 SD in marginal zone lymphoma; 2 SDs in follicular lymphoma - Fred Hutchinson preclinical models with STRO-001 identifies CD74 as a potential target for the treatment of AML

- Data from the CITADEL program of parsaclisib in patients with follicular, marginal zone and mantle cell lymphomas were accepted for presentation at the 62nd American Society of Hematology Annual Meeting and Exposition (ASH 2020) - Investor conference call and webcast scheduled for today, December 7, at 10:00 a.m. ET (7:00 a.m. PT)

TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentation of data from the UNITY-CLL Phase 3 trial

Eisai Inc. presented 52-week seizure freedom data related to its antiepileptic drug (AED) FYCOMPA® (perampanel) CIII at the 2020 American Epilepsy Society (AES) Annual Meeting virtual conference.

[07-December-2020] WOONSOCKET, R.I. , Dec. 7, 2020 /PRNewswire/ -- CVS Health Corporation (“CVS Health”, NYSE: CVS) announced today that it has commenced cash tender offers (each, a “Tender Offer” and collectively, the “Tender Offers”) for (i) up to $1,500,000,000 aggregate principal amount (the “2023 Notes Maximum Amount”) of its 4.000% Senior Notes due 2023 and 3.700% Senior Notes due 2023 a

Cellworks Group , Inc., a world leader in Personalized Medicine in the key therapeutic areas of Oncology and Immunology, today announced results from the myCare-021-01 clinical trial, which found that the Cellworks Omics Biology Model (CBM) predicted response to Arsenic Trioxide (ATO) and All-trans-retinoic Acid (ATRA) in Acute Promyelocytic Leukemia (APL) patients harboring PML-RARA fusions with 93% accuracy.

On December 3, 2020, Luminex Corporation, announced that its board of directors approved a $0.01 increase in the quarterly dividend, to $0.10 per share of common stock, payable on January 14, 2021 to stockholders of record as of the close of business December 23, 2021.

DURECT Corporation (Nasdaq: DRRX) today announced that it has signed an agreement to sell its LACTEL Absorbable Polymer (LACTEL) product line to Evonik, a global leader in specialty chemicals. Under the terms of the agreement, Evonik will pay DURECT $15 million in exchange for certain assets and liabilities associated with